Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2004 1
2006 2
2008 1
2009 1
2011 1
2012 2
2015 2
2016 5
2017 3
2018 1
2019 3
2020 3
2021 5
2022 4
2023 5
2024 6
2025 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

51 results

Results by year

Filters applied: . Clear all
Page 1
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
Miles D, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Campone M, Bondarenko I, Nowecki Z, Errihani H, Paluch-Shimon S, Wardley A, Merot JL, Trask P, du Toit Y, Pena-Murillo C, Revelant V, Klingbiel D, Bachelot T; PERUSE investigators. Miles D, et al. Ann Oncol. 2021 Oct;32(10):1245-1255. doi: 10.1016/j.annonc.2021.06.024. Epub 2021 Jul 2. Ann Oncol. 2021. PMID: 34224826 Free article. Clinical Trial.
Therapeutic tools for oral candidiasis: Current and new antifungal drugs.
Quindós G, Gil-Alonso S, Marcos-Arias C, Sevillano E, Mateo E, Jauregizar N, Eraso E. Quindós G, et al. Among authors: sevillano e. Med Oral Patol Oral Cir Bucal. 2019 Mar 1;24(2):e172-e180. doi: 10.4317/medoral.22978. Med Oral Patol Oral Cir Bucal. 2019. PMID: 30818309 Free PMC article. Review.
Multicenter study correlating molecular characteristics and clinical outcomes of cancer cases with patient-derived organoids.
Navarro P, Grazioso TP, Barquín A, Barba M, Yagüe M, Millán C, López I, Sevillano E, Quiralte M, Fernández P, Losada D, Caleiras E, Calzas J, Jiménez B, Ruiz-Llorente S, Justo J, Guerrero F, Hevia V, Martín R, Pérez-Rodriguez FJ, Tejerina J, Prieto M, Comune P, Rodriguez-Moreno JF, García-Donás J. Navarro P, et al. Among authors: sevillano e. J Exp Clin Cancer Res. 2025 Jul 2;44(1):182. doi: 10.1186/s13046-025-03437-0. J Exp Clin Cancer Res. 2025. PMID: 40605011 Free PMC article.
New insights and emerging approaches in bladder-sparing treatment for muscle-invasive bladder cancer.
Subiela JD, Guerrero-Ramos F, Rodríguez-Faba Ó, Aumatell J, Gajate P, López-Campos F, Sevillano E, Hernández-Arroyo M, García-Rojo E, Artiles Medina A, Sáenz-Calzada D, Gómez-Cañizo C, Romero-Otero J, Couñago F. Subiela JD, et al. Among authors: sevillano e. Actas Urol Esp (Engl Ed). 2025 Sep;49(7):501758. doi: 10.1016/j.acuroe.2025.501758. Epub 2025 Apr 19. Actas Urol Esp (Engl Ed). 2025. PMID: 40258413 Review. English, Spanish.
Phase II clinical trial assessing the efficacy of enzalutamide in advanced non-resectable granulosa cell ovarian tumors: The GREKO III study (GETHI2016-01).
García-Donas J, Redondo A, Santaballa A, Garrigos L, Rubio MJ, Lainez N, González MI, Cueva JF, Barquin A, Grazioso TP, Hurtado A, Sevillano E, Grande E, Rodriguez-Moreno JF, Navarro P. García-Donas J, et al. Among authors: sevillano e. Gynecol Oncol. 2024 Dec;191:233-239. doi: 10.1016/j.ygyno.2024.10.019. Epub 2024 Oct 24. Gynecol Oncol. 2024. PMID: 39454227 Clinical Trial.
51 results